[ad_1]
The new vision for life sciences sets out a 10-year strategy for the sector to address the main health challenges of the generation, including cancer and dementia.
The Government of the United Kingdom (UK) aims to accelerate the delivery of new innovations in patient care through the New UK Vision for Life Sciences launched on July 6.
Britain’s vision for life sciences sees it as a ‘bold ambition for the next decade to ensure scientific excellence, in partnership with industry dynamics’, essentially reoriented to augment the National Health System (NHS) in order to solve urgent health challenges. In total, £ 1bn of new funding is available for Britain’s most promising life sciences companies, with the potential to attract additional funding from other investors.
This investment vision targets seven (7) critical health care missions that government, industry, NHS, universities and medical research organizations to collaborate at full throttle to solve emerging health issues, from cancer to dementia.
The central aim of Life Sciences Vision is to cultivate a business environment in which UK life science companies can access funding to innovate and grow, are regulated in an agile and efficient manner. With a focus on supporting private sector businesses, a pro-business environment program and access to capital, encouraging onshore production while marketing their drugs and devices in the UK.
The UK government has launched its Life Sciences Investment Program with a £ 200million investment to unleash the potential of innovative UK life science companies.
These missions will focus on:
- Prevention, diagnosis, disease surveillance and early treatment of disease
- Development of disruptive products and treatments through innovative clinical trials
- Accelerate the development and adoption of new drugs, diagnostics, medical technologies and digital tools
The objectives of the mission are to:
- Speeding up the pace of studies on a new treatment for dementia
- Allow early diagnosis and treatment, including immune therapies such as cancer vaccines
- Maintain UK position in vaccine discovery, development and manufacture
- Treatment and prevention of cardiovascular disease and its main risk factors, including obesity
- Reduce mortality and morbidity from respiratory diseases in the UK and globally
- Address the underlying biology of aging
- Increase understanding of mental health issues, including work to redefine illnesses and develop tools to treat them
The vision seeks to emulate the successes of the UK Vaccine Task Force – harnessing private sector expertise and removing unnecessary bureaucracy so that the most savvy UK industry leaders can tackle future healthcare challenges quickly and at risk.
The new vision will guarantee the regulatory freedoms and opportunities that currently lie with the European Union. The Medicines and Health Products Regulatory Agency (MHRA) will be able to act as an independent and sovereign regulator.
[ad_2]
Source link
